Biomarkers in idiopathic pulmonary fibrosis

Matrix Biology

Volumn 68-69, Issue , 2018, Pages 404-421

  Drakopanagiotakis, F ^a   Wujak, Lukasz ^b   Wygrecka, Malgorzata ^b   Markart, P ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Biomarkers; IPF; Matrix metalloprotease; MUC5B

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; C-C MOTIF CHEMOKINE 18; CALGRANULIN C; CHITINASE 3 LIKE PROTEIN 1; CXCL13 CHEMOKINE; CYTOKERATIN 18; DEFENSIN; GLYCOPROTEIN; HEAT SHOCK PROTEIN 70 ANTIBODY; KREBS VON DEN LUNGEN 6; LYSYL OXIDASE LIKE PROTEIN; MATRIX METALLOPROTEINASE; MITOCHONDRIAL DNA; MUCIN 5B; OSTEOPONTIN; PROTEIN; SURFACTANT PROTEIN; TOLL INTERACTING PROTEIN; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; VIMENTIN; MUC5B PROTEIN, HUMAN; SIGNAL PEPTIDE; TOLLIP PROTEIN, HUMAN;

ADAPTIVE IMMUNITY; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROCYTE; FIBROSING ALVEOLITIS; HUMAN; INNATE IMMUNITY; LUNG ALVEOLUS EPITHELIUM CELL; MICROBIOME; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; REVIEW; STEM CELL; T LYMPHOCYTE SUBPOPULATION; TELOMERE; BLOOD; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; EARLY DIAGNOSIS; GENETICS; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; PROGNOSIS;

BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DNA, MITOCHONDRIAL; EARLY DIAGNOSIS; GASTROINTESTINAL MICROBIOME; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUCIN-5B; PROGNOSIS;

EID: 85042064425     PISSN: 0945053X     EISSN: 15691802     Source Type: Journal    
DOI: 10.1016/j.matbio.2018.01.023     Document Type: Review

References (176)

1. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Muller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schunemann, H.J., A.E.J.A.C.o.I.P. Fibrosis, An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183:6 (2011), 788–824.
2. Behr, J., Guidelines or guidance for better idiopathic pulmonary fibrosis management?. BMC Med., 14, 2016, 24.
3. New guidelines for idiopathic pulmonary fibrosis. Lancet, 386(9991), 2015, 312.
4. Tzilas, V., Valeyre, D., Tzouvelekis, A., Bouros, D., Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis. Lancet Respir. Med. 6, No. 2 (2017), 82–84 pii: S2213-2600(17)30443-5 https://doi.org/10.1016/S2213-2600(17)30443-5 (Epub ahead of print).
5. Lynch, D.A., Sverzellati, N., Travis, W.D., Brown, K.K., Colby, T.V., Galvin, J.R., Goldin, J.G., Hansell, D.M., Inoue, Y., Johkoh, T., Nicholson, A.G., Knight, S.L., Raoof, S., Richeldi, L., Ryerson, C.J., Ryu, J.H., Wells, A.U., Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir. Med. 6, No. 2 (2017), 138–153 pii: S2213-2600(17)30433-2 https://doi.org/10.1016/S2213-2600(17)30433-2 (Epub ahead of print).
6. Martinez, F.J., Collard, H.R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J.J., Taniguchi, H., Wells, A.U., Idiopathic pulmonary fibrosis. Nat. Rev. Dis. Prim., 3, 2017, 17074.
7. Walsh, S.L.F., Maher, T.M., Kolb, M., Poletti, V., Nusser, R., Richeldi, L., Vancheri, C., Wilsher, M.L., Antoniou, K.M., Behr, J., Bendstrup, E., Brown, K., Calandriello, L., Corte, T.J., Cottin, V., Crestani, B., Flaherty, K., Glaspole, I., Grutters, J., Inoue, Y., Kokosi, M., Kondoh, Y., Kouranos, V., Kreuter, M., Johannson, K., Judge, E., Ley, B., Margaritopoulos, G., Martinez, F.J., Molina-Molina, M., Morais, A., Nunes, H., Raghu, G., Ryerson, C.J., Selman, M., Spagnolo, P., Taniguchi, H., Tomassetti, S., Valeyre, D., Wijsenbeek, M., Wuyts, W., Hansell, D., Wells, A., Consortium, I.P.F.P., Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. Eur. Respir. J., 50(2), 2017.
8. Mora, A.L., Rojas, M., Pardo, A., Selman, M., Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat. Rev. Drug Discov. 16:11 (2017), 755–772.
9. Oldham, J.M., Noth, I., Martinez, F.J., Pharmacogenetics and interstitial lung disease. Curr. Opin. Pulm. Med. 22:5 (2016), 456–465.
10. Collard, H.R., Bradford, W.Z., Cottin, V., Flaherty, K.R., King, T.E. Jr., Koch, G.G., Kolb, M., Martinez, F.J., Montgomery, B., Raghu, G., Richeldi, L., Rose, D., Wells, A.U., Brown, K.K., A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. Eur. Respir. J. 46:1 (2015), 243–249.
11. Magnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R.E., Lo Greco, E., Bruni, T., Fabbrizzi, A., Lombardi, F., Richeldi, L., Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies. Respiration 93:6 (2017), 379–395.
12. Rindlisbacher, B., Strebel, C., Guler, S., Kollar, A., Geiser, T., Martin Fiedler, G., Benedikt Leichtle, A., Bovet, C., Funke-Chambour, M., Exhaled breath condensate as a potential biomarker tool for idiopathic pulmonary fibrosis-a pilot study. J. Breath Res., 12(1), 2017, 016003.
13. Tzouvelekis, A., Herazo-Maya, J., Sakamoto, K., Bouros, D., Biomarkers in the evaluation and management of idiopathic pulmonary fibrosis. Curr. Top. Med. Chem. 16:14 (2016), 1587–1598.
14. Guiot, J., Henket, M., Corhay, J.L., Moermans, C., Louis, R., Sputum biomarkers in IPF: evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. PLoS One, 12(2), 2017, e0171344.
15. Guiot, J., Moermans, C., Henket, M., Corhay, J.L., Louis, R., Blood biomarkers in idiopathic pulmonary fibrosis. Lung 195:3 (2017), 273–280.
16. Yamada, Y.I., Yamada, G., Otsuka, M., Nishikiori, H., Ikeda, K., Umeda, Y., Ohnishi, H., Kuronuma, K., Chiba, H., Baumbach, J.I., Takahashi, H., Volatile organic compounds in exhaled breath of idiopathic pulmonary fibrosis for discrimination from healthy subjects. Lung 195:2 (2017), 247–254.
17. Kokosi, M.A., Renzoni, E., Bonella, F., Biomarkers, in monograph: idiopathic pulmonary fibrosis. Eur. Res. Soc., 2016, 122–142.
18. Kaarteenaho, R., Lappi-Blanco, E., Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair, 8, 2015, 3.
19. Spagnolo, P., Tzouvelekis, A., Maher, T.M., Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr. Opin. Pulm. Med. 21:5 (2015), 470–478.
20. Lunardi, F., Balestro, E., Nannini, N., Vuljan, S.E., Rea, F., Calabrese, F., Idiopathic pulmonary fibrosis: are any of the morphological-molecular markers useful in clinical management?. Histol. Histopathol. 32:7 (2017), 661–672.
21. Ley, B., Brown, K.K., Collard, H.R., Molecular biomarkers in idiopathic pulmonary fibrosis. Am. J. Phys. Lung Cell. Mol. Phys. 307:9 (2014), L681–91.
22. Hambly, N., Shimbori, C., Kolb, M., Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers. Respirology 20:7 (2015), 1010–1022.
23. Selman, M., King, T.E., Pardo, A., S. American Thoracic, S. European Respiratory, P. American College of Chest, Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134:2 (2001), 136–151.
24. King, T.E. Jr., Schwarz, M.I., Brown, K., Tooze, J.A., Colby, T.V., Waldron, J.A. Jr., Flint, A., Thurlbeck, W., Cherniack, R.M., Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am. J. Respir. Crit. Care Med. 164:6 (2001), 1025–1032.
25. Tatler, A.L., Jenkins, G., TGF-beta activation and lung fibrosis. Proc. Am. Thorac. Soc. 9:3 (2012), 130–136.
26. Selman, M., Pardo, A., Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am. J. Respir. Crit. Care Med. 189:10 (2014), 1161–1172.
27. O'Dwyer, D.N., Ashley, S.L., Moore, B.B., Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis. Am. J. Phys. Lung Cell. Mol. Phys. 311:3 (2016), L590–601.
28. Schafer, M.J., White, T.A., Iijima, K., Haak, A.J., Ligresti, G., Atkinson, E.J., Oberg, A.L., Birch, J., Salmonowicz, H., Zhu, Y., Mazula, D.L., Brooks, R.W., Fuhrmann-Stroissnigg, H., Pirtskhalava, T., Prakash, Y.S., Tchkonia, T., Robbins, P.D., Aubry, M.C., Passos, J.F., Kirkland, J.L., Tschumperlin, D.J., Kita, H., LeBrasseur, N.K., Cellular senescence mediates fibrotic pulmonary disease. Nat. Commun., 8, 2017, 14532.
29. Yokoyama, A., Kohno, N., Hamada, H., Sakatani, M., Ueda, E., Kondo, K., Hirasawa, Y., Hiwada, K., Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 158:5 Pt 1 (1998), 1680–1684.
30. Okamoto, T., Fujii, M., Furusawa, H., Tsuchiya, K., Miyazaki, Y., Inase, N., The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir. Med. 109:12 (2015), 1576–1581.
31. Xu, L., Bian, W., Gu, X.H., Shen, C., Differing expression of cytokines and tumor markers in combined pulmonary fibrosis and emphysema compared to emphysema and pulmonary fibrosis. COPD 14:2 (2017), 245–250.
32. Hamai, K., Iwamoto, H., Ishikawa, N., Horimasu, Y., Masuda, T., Miyamoto, S., Nakashima, T., Ohshimo, S., Fujitaka, K., Hamada, H., Hattori, N., Kohno, N., Comparative study of circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as disease markers of idiopathic pulmonary fibrosis. Dis. Markers, 2016, 2016, 4759040.
33. Yokoyama, A., Kondo, K., Nakajima, M., Matsushima, T., Takahashi, T., Nishimura, M., Bando, M., Sugiyama, Y., Totani, Y., Ishizaki, T., Ichiyasu, H., Suga, M., Hamada, H., Kohno, N., Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 11:2 (2006), 164–168.
34. Wakamatsu, K., Nagata, N., Kumazoe, H., Oda, K., Ishimoto, H., Yoshimi, M., Takata, S., Hamada, M., Koreeda, Y., Takakura, K., Ishizu, M., Hara, M., Ise, S., Izumi, M., Akasaki, T., Maki, S., Kawabata, M., Mukae, H., Kawasaki, M., Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis. Respir. Investig. 55:1 (2017), 16–23.
35. Sokai, A., Tanizawa, K., Handa, T., Kanatani, K., Kubo, T., Ikezoe, K., Nakatsuka, Y., Tokuda, S., Oga, T., Hirai, T., Nagai, S., Chin, K., Mishima, M., Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res., 3(3), 2017.
36. Qiu, M., Chen, Y., Ye, Q., Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin. Respir. J. 00 (2017), 1–9.
37. Ohshimo, S., Ishikawa, N., Horimasu, Y., Hattori, N., Hirohashi, N., Tanigawa, K., Kohno, N., Bonella, F., Guzman, J., Costabel, U., Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir. Med. 108:7 (2014), 1031–1039.
38. Kohno, N., Awaya, Y., Oyama, T., Yamakido, M., Akiyama, M., Inoue, Y., Yokoyama, A., Hamada, H., Fujioka, S., Hiwada, K., KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am. Rev. Respir. Dis. 148:3 (1993), 637–642.
39. Gunther, A., Korfei, M., Mahavadi, P., von der Beck, D., Ruppert, C., Markart, P., Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur. Respir. Rev. 21:124 (2012), 152–160.
40. Mulugeta, S., Nureki, S., Beers, M.F., Lost after translation: insights from pulmonary surfactant for understanding the role of alveolar epithelial dysfunction and cellular quality control in fibrotic lung disease. Am. J. Phys. Lung Cell. Mol. Phys. 309:6 (2015), L507–25.
41. Lawson, W.E., Crossno, P.F., Polosukhin, V.V., Roldan, J., Cheng, D.S., Lane, K.B., Blackwell, T.R., Xu, C., Markin, C., Ware, L.B., Miller, G.G., Loyd, J.E., Blackwell, T.S., Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am. J. Phys. Lung Cell. Mol. Phys. 294:6 (2008), L1119–26.
42. Tanjore, H., Blackwell, T.S., Lawson, W.E., Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Phys. Lung Cell. Mol. Phys. 302:8 (2012), L721–9.
43. Korfei, M., Ruppert, C., Mahavadi, P., Henneke, I., Markart, P., Koch, M., Lang, G., Fink, L., Bohle, R.M., Seeger, W., Weaver, T.E., Guenther, A., Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178:8 (2008), 838–846.
44. Honda, Y., Kuroki, Y., Matsuura, E., Nagae, H., Takahashi, H., Akino, T., Abe, S., Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am. J. Respir. Crit. Care Med. 152:6 Pt 1 (1995), 1860–1866.
45. Kuroki, Y., Tsutahara, S., Shijubo, N., Takahashi, H., Shiratori, M., Hattori, A., Honda, Y., Abe, S., Akino, T., Elevated levels of lung surfactant protein A in sera from patients with idiopathic pulmonary fibrosis and pulmonary alveolar proteinosis. Am. Rev. Respir. Dis. 147:3 (1993), 723–729.
46. Greene, K.E., King, T.E. Jr., Kuroki, Y., Bucher-Bartelson, B., Hunninghake, G.W., Newman, L.S., Nagae, H., Mason, R.J., Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur. Respir. J. 19:3 (2002), 439–446.
47. Gunther, A., Schmidt, R., Nix, F., Yabut-Perez, M., Guth, C., Rosseau, S., Siebert, C., Grimminger, F., Morr, H., Velcovsky, H.G., Seeger, W., Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur. Respir. J. 14:3 (1999), 565–573.
48. McCormack, F.X., King, T.E. Jr., Bucher, B.L., Nielsen, L., Mason, R.J., Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 152:2 (1995), 751–759.
49. Takahashi, H., Shiratori, M., Kanai, A., Chiba, H., Kuroki, Y., Abe, S., Monitoring markers of disease activity for interstitial lung diseases with serum surfactant proteins A and D. Respirology 11:Suppl (2006), S51–4.
50. Takahashi, H., Fujishima, T., Koba, H., Murakami, S., Kurokawa, K., Shibuya, Y., Shiratori, M., Kuroki, Y., Abe, S., Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am. J. Respir. Crit. Care Med. 162:3 Pt 1 (2000), 1109–1114.
51. Collard, H.R., Calfee, C.S., Wolters, P.J., Song, J.W., Hong, S.B., Brady, S., Ishizaka, A., Jones, K.D., King, T.E. Jr., Matthay, M.A., Kim, D.S., Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am. J. Phys. Lung Cell. Mol. Phys. 299:1 (2010), L3–7.
52. Wang, K., Ju, Q., Cao, J., Tang, W., Zhang, J., Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Medicine (Baltimore), 96(23), 2017, e7083.
53. Garcia, C.K., Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc. Am. Thorac. Soc. 8:2 (2011), 158–162.
54. Nathan, N., Giraud, V., Picard, C., Nunes, H., Dastot-Le Moal, F., Copin, B., Galeron, L., De Ligniville, A., Kuziner, N., Reynaud-Gaubert, M., Valeyre, D., Couderc, L.J., Chinet, T., Borie, R., Crestani, B., Simansour, M., Nau, V., Tissier, S., Duquesnoy, P., Mansour-Hendili, L., Legendre, M., Kannengiesser, C., Coulomb-L'Hermine, A., Gouya, L., Amselem, S., Clement, A., Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum. Mol. Genet. 25:8 (2016), 1457–1467.
55. Wang, Y., Kuan, P.J., Xing, C., Cronkhite, J.T., Torres, F., Rosenblatt, R.L., DiMaio, J.M., Kinch, L.N., Grishin, N.V., Garcia, C.K., Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 84:1 (2009), 52–59.
56. Sears, P.R., Davis, C.W., Chua, M., Sheehan, J.K., Mucociliary interactions and mucus dynamics in ciliated human bronchial epithelial cell cultures. Am. J. Phys. Lung Cell. Mol. Phys. 301:2 (2011), L181–6.
57. Sharma, P., Dudus, L., Nielsen, P.A., Clausen, H., Yankaskas, J.R., Hollingsworth, M.A., Engelhardt, J.F., MUC5B and MUC7 are differentially expressed in mucous and serous cells of submucosal glands in human bronchial airways. Am. J. Respir. Cell Mol. Biol. 19:1 (1998), 30–37.
58. Seibold, M.A., Smith, R.W., Urbanek, C., Groshong, S.D., Cosgrove, G.P., Brown, K.K., Schwarz, M.I., Schwartz, D.A., Reynolds, S.D., The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One, 8(3), 2013, e58658.
59. Seibold, M.A., Wise, A.L., Speer, M.C., Steele, M.P., Brown, K.K., Loyd, J.E., Fingerlin, T.E., Zhang, W., Gudmundsson, G., Groshong, S.D., Evans, C.M., Garantziotis, S., Adler, K.B., Dickey, B.F., du Bois, R.M., Yang, I.V., Herron, A., Kervitsky, D., Talbert, J.L., Markin, C., Park, J., Crews, A.L., Slifer, S.H., Auerbach, S., Roy, M.G., Lin, J., Hennessy, C.E., Schwarz, M.I., Schwartz, D.A., A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 364:16 (2011), 1503–1512.
60. Noth, I., Zhang, Y., Ma, S.F., Flores, C., Barber, M., Huang, Y., Broderick, S.M., Wade, M.S., Hysi, P., Scuirba, J., Richards, T.J., Juan-Guardela, B.M., Vij, R., Han, M.K., Martinez, F.J., Kossen, K., Seiwert, S.D., Christie, J.D., Nicolae, D., Kaminski, N., Garcia, J.G.N., Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir. Med. 1:4 (2013), 309–317.
61. Fingerlin, T.E., Murphy, E., Zhang, W., Peljto, A.L., Brown, K.K., Steele, M.P., Loyd, J.E., Cosgrove, G.P., Lynch, D., Groshong, S., Collard, H.R., Wolters, P.J., Bradford, W.Z., Kossen, K., Seiwert, S.D., du Bois, R.M., Garcia, C.K., Devine, M.S., Gudmundsson, G., Isaksson, H.J., Kaminski, N., Zhang, Y., Gibson, K.F., Lancaster, L.H., Cogan, J.D., Mason, W.R., Maher, T.M., Molyneaux, P.L., Wells, A.U., Moffatt, M.F., Selman, M., Pardo, A., Kim, D.S., Crapo, J.D., Make, B.J., Regan, E.A., Walek, D.S., Daniel, J.J., Kamatani, Y., Zelenika, D., Smith, K., McKean, D., Pedersen, B.S., Talbert, J., Kidd, R.N., Markin, C.R., Beckman, K.B., Lathrop, M., Schwarz, M.I., Schwartz, D.A., Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat. Genet. 45:6 (2013), 613–620.
62. Peljto, A.L., Zhang, Y., Fingerlin, T.E., Ma, S.F., Garcia, J.G., Richards, T.J., Silveira, L.J., Lindell, K.O., Steele, M.P., Loyd, J.E., Gibson, K.F., Seibold, M.A., Brown, K.K., Talbert, J.L., Markin, C., Kossen, K., Seiwert, S.D., Murphy, E., Noth, I., Schwarz, M.I., Kaminski, N., Schwartz, D.A., Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309:21 (2013), 2232–2239.
63. Zhang, Y., Noth, I., Garcia, J.G.N., Kaminski, N., A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N. Engl. J. Med. 364:16 (2011), 1576–1577.
64. Wang, C., Zhuang, Y., Guo, W., Cao, L., Zhang, H., Xu, L., Fan, Y., Zhang, D., Wang, Y., Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males. PLoS One, 9(8), 2014, e104919.
65. Borie, R., Crestani, B., Dieude, P., Nunes, H., Allanore, Y., Kannengiesser, C., Airo, P., Matucci-Cerinic, M., Wallaert, B., Israel-Biet, D., Cadranel, J., Cottin, V., Gazal, S., Peljto, A.L., Varga, J., Schwartz, D.A., Valeyre, D., Grandchamp, B., The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One, 8(8), 2013, e70621.
66. Chung, J.H., Peljto, A.L., Chawla, A., Talbert, J.L., McKean, D.F., Rho, B.H., Fingerlin, T.E., Schwarz, M.I., Schwartz, D.A., Lynch, D.A., CT imaging phenotypes of pulmonary fibrosis in the MUC5B promoter site polymorphism. Chest 149:5 (2016), 1215–1222.
67. Stock, C.J., Sato, H., Fonseca, C., Banya, W.A., Molyneaux, P.L., Adamali, H., Russell, A.M., Denton, C.P., Abraham, D.J., Hansell, D.M., Nicholson, A.G., Maher, T.M., Wells, A.U., Lindahl, G.E., Renzoni, E.A., Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68:5 (2013), 436–441.
68. Ley, B., Newton, C.A., Arnould, I., Elicker, B.M., Henry, T.S., Vittinghoff, E., Golden, J.A., Jones, K.D., Batra, K., Torrealba, J., Garcia, C.K., Wolters, P.J., The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir. Med. 5:8 (2017), 639–647.
69. Hunninghake, G.M., Hatabu, H., Okajima, Y., Gao, W., Dupuis, J., Latourelle, J.C., Nishino, M., Araki, T., Zazueta, O.E., Kurugol, S., Ross, J.C., San Jose, R., Estepar, E. Murphy, Steele, M.P., Loyd, J.E., Schwarz, M.I., Fingerlin, T.E., Rosas, I.O., Washko, G.R., O'Connor, G.T., Schwartz, D.A., MUC5B promoter polymorphism and interstitial lung abnormalities. N. Engl. J. Med. 368:23 (2013), 2192–2200.
70. Araki, T., Putman, R.K., Hatabu, H., Gao, W., Dupuis, J., Latourelle, J.C., Nishino, M., Zazueta, O.E., Kurugol, S., Ross, J.C., San Jose, R., Estepar, D.A. Schwartz, Rosas, I.O., Washko, G.R., O'Connor, G.T., Hunninghake, G.M., Development and progression of interstitial lung abnormalities in the Framingham heart study. Am. J. Respir. Crit. Care Med. 194:12 (2016), 1514–1522.
71. Ash, S.Y., Harmouche, R., Putman, R.K., Ross, J.C., Diaz, A.A., Hunninghake, G.M., Onieva Onieva, J., Martinez, F.J., Choi, A.M., Lynch, D.A., Hatabu, H., Rosas, I.O., San Jose, R., Estepar, G.R. Washko, Investigators, C.O., Clinical and genetic associations of objectively identified interstitial changes in smokers. Chest 152:4 (2017), 780–791.
72. Cha, S.I., Ryerson, C.J., Lee, J.S., Kukreja, J., Barry, S.S., Jones, K.D., Elicker, B.M., Kim, D.S., Papa, F.R., Collard, H.R., Wolters, P.J., Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respir. Res., 13, 2012, 105.
73. Stanley, S.E., Armanios, M., Short telomeres: a repeat offender in IPF. Lancet Respir. Med. 2:7 (2014), 513–514.
74. Thannickal, V.J., Mechanistic links between aging and lung fibrosis. Biogerontology 14:6 (2013), 609–615.
75. Armanios, M., Telomerase and idiopathic pulmonary fibrosis. Mutat. Res. 730:1-2 (2012), 52–58.
76. Naikawadi, R.P., Disayabutr, S., Mallavia, B., Donne, M.L., Green, G., La, J.L., Rock, J.R., Looney, M.R., Wolters, P.J., Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis. JCI Insight, 1(14), 2016, e86704.
77. Armanios, M.Y., Chen, J.J., Cogan, J.D., Alder, J.K., Ingersoll, R.G., Markin, C., Lawson, W.E., Xie, M., Vulto, I., Phillips, J.A., 3rd, P.M. Lansdorp, Greider, C.W., Loyd, J.E., Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356:13 (2007), 1317–1326.
78. Tsakiri, K.D., Cronkhite, J.T., Kuan, P.J., Xing, C., Raghu, G., Weissler, J.C., Rosenblatt, R.L., Shay, J.W., Garcia, C.K., Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl. Acad. Sci. U. S. A. 104:18 (2007), 7552–7557.
79. Alder, J.K., Chen, J.J., Lancaster, L., Danoff, S., Su, S.C., Cogan, J.D., Vulto, I., Xie, M., Qi, X., Tuder, R.M., Phillips, J.A., 3rd, P.M. Lansdorp, Loyd, J.E., Armanios, M.Y., Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. U. S. A. 105:35 (2008), 13051–13056.
80. Petrovski, S., Todd, J.L., Durheim, M.T., Wang, Q., Chien, J.W., Kelly, F.L., Frankel, C., Mebane, C.M., Ren, Z., Bridgers, J., Urban, T.J., Malone, C.D., Finlen Copeland, A., Brinkley, C., Allen, A.S., O'Riordan, T., McHutchison, J.G., Palmer, S.M., Goldstein, D.B., An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 196:1 (2017), 82–93.
81. Kropski, J.A., Mitchell, D.B., Markin, C., Polosukhin, V.V., Choi, L., Johnson, J.E., Lawson, W.E., Phillips, J.A., 3rd, J.D. Cogan, Blackwell, T.S., Loyd, J.E., A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest, 146(1), 2014, e1-e7.
82. Borie, R., Kannengiesser, C., Hirschi, S., Le Pavec, J., Mal, H., Bergot, E., Jouneau, S., Naccache, J.M., Revy, P., Boutboul, D., Peffault de la Tour, R., Wemeau-Stervinou, L., Philit, F., Cordier, J.F., Thabut, G., Crestani, B., Cottin, V., P. Groupe d'Etudes et de Recherche sur les Maladies Orphelines, Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. J Heart Lung Transplant 34:4 (2015), 538–546.
83. Cronkhite, J.T., Xing, C., Raghu, G., Chin, K.M., Torres, F., Rosenblatt, R.L., Garcia, C.K., Telomere shortening in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178:7 (2008), 729–737.
84. Henry, M.T., McMahon, K., Mackarel, A.J., Prikk, K., Sorsa, T., Maisi, P., Sepper, R., Fitzgerald, M.X., O'Connor, C.M., Matrix metalloproteinases and tissue inhibitor of metalloproteinase-1 in sarcoidosis and IPF. Eur. Respir. J. 20:5 (2002), 1220–1227.
85. Ramos, C., Montano, M., Garcia-Alvarez, J., Ruiz, V., Uhal, B.D., Selman, M., Pardo, A., Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am. J. Respir. Cell Mol. Biol. 24:5 (2001), 591–598.
86. Suga, M., Iyonaga, K., Okamoto, T., Gushima, Y., Miyakawa, H., Akaike, T., Ando, M., Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 162:5 (2000), 1949–1956.
87. Dancer, R.C., Wood, A.M., Thickett, D.R., Metalloproteinases in idiopathic pulmonary fibrosis. Eur. Respir. J. 38:6 (2011), 1461–1467.
88. Craig, V.J., Zhang, L., Hagood, J.S., Owen, C.A., Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 53:5 (2015), 585–600.
89. Rosas, I.O., Richards, T.J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A.E., Lindell, K.O., Cisneros, J., Macdonald, S.D., Pardo, A., Sciurba, F., Dauber, J., Selman, M., Gochuico, B.R., Kaminski, N., MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med., 5(4), 2008, e93.
90. Tzouvelekis, A., Herazo-Maya, J.D., Slade, M., Chu, J.H., Deiuliis, G., Ryu, C., Li, Q., Sakamoto, K., Ibarra, G., Pan, H., Gulati, M., Antin-Ozerkis, D., Herzog, E.L., Kaminski, N., Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology 22:3 (2017), 486–493.
91. Morais, A., Beltrao, M., Sokhatska, O., Costa, D., Melo, N., Mota, P., Marques, A., Delgado, L., Serum metalloproteinases 1 and 7 in the diagnosis of idiopathic pulmonary fibrosis and other interstitial pneumonias. Respir. Med. 109:8 (2015), 1063–1068.
92. Bauer, Y., White, E.S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., Nayler, O., MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis. ERJ Open Res., 3(1), 2017.
93. Song, J.W., Do, K.H., Jang, S.J., Colby, T.V., Han, S., Kim, D.S., Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest 143:5 (2013), 1422–1429.
94. Armstrong, H.F., Podolanczuk, A.J., Barr, R.G., Oelsner, E.C., Kawut, S.M., Hoffman, E.A., Tracy, R., Kaminski, N., McClelland, R.L., Lederer, D.J., Serum matrix metalloproteinase-7, respiratory symptoms, and mortality in community-dwelling adults: the multi-ethnic study of atherosclerosis. Am. J. Respir. Crit. Care Med. 196:10 (2017), 1311–1317.
95. Aumiller, V., Strobel, B., Romeike, M., Schuler, M., Stierstorfer, B.E., Kreuz, S., Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis. Sci. Rep., 7(1), 2017, 149.
96. Philp, C.J., Siebeke, I., Clements, D., Miller, S., Habgood, A., John, A.E., Navaratnam, V., Hubbard, R.B., Jenkins, G., Johnson, S.R., ECM crosslinking enhances fibroblast growth and protects against matrix proteolysis in lung fibrosis. Am. J. Respir. Cell Mol. Biol., 2017.
97. Chien, J.W., Richards, T.J., Gibson, K.F., Zhang, Y., Lindell, K.O., Shao, L., Lyman, S.K., Adamkewicz, J.I., Smith, V., Kaminski, N., O'Riordan, T., Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur. Respir. J. 43:5 (2014), 1430–1438.
98. Raghu, G., Brown, K.K., Collard, H.R., Cottin, V., Gibson, K.F., Kaner, R.J., Lederer, D.J., Martinez, F.J., Noble, P.W., Song, J.W., Wells, A.U., Whelan, T.P., Wuyts, W., Moreau, E., Patterson, S.D., Smith, V., Bayly, S., Chien, J.W., Gong, Q., Zhang, J.J., O'Riordan, T.G., Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respir. Med. 5:1 (2017), 22–32.
99. Bucala, R., Spiegel, L.A., Chesney, J., Hogan, M., Cerami, A., Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1:1 (1994), 71–81.
100. Andersson-Sjoland, A., de Alba, C.G., Nihlberg, K., Becerril, C., Ramirez, R., Pardo, A., Westergren-Thorsson, G., Selman, M., Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int. J. Biochem. Cell Biol. 40:10 (2008), 2129–2140.
101. Moeller, A., Gilpin, S.E., Ask, K., Cox, G., Cook, D., Gauldie, J., Margetts, P.J., Farkas, L., Dobranowski, J., Boylan, C., O'Byrne, P.M., Strieter, R.M., Kolb, M., Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179:7 (2009), 588–594.
102. Alhamad, E.H., Shakoor, Z., Al-Kassimi, F.A., Almogren, A., Gad, M.O., ElRab, S. Maharaj, Kolb, M., Rapid detection of circulating fibrocytes by flowcytometry in idiopathic pulmonary fibrosis. Ann. Thorac. Med. 10:4 (2015), 279–283.
103. Tomaru, A., Kobayashi, T., Hinneh, J.A., Tonto, P.B., CN, D.A.-G., Fujimoto, H., Fujiwara, K., Takahashi, Y., Ohnishi, M., Yasuma, T., Nishihama, K., Yoshino, M., Takao, K., Toda, M., Totoki, T., Takei, Y., Yoshikawa, K., Taguchi, O., Gabazza, E.C., Oligonucleotides targeting periostin ameliorates pulmonary fibrosis. Gene Ther. 24 (2017), 706–716.
104. Okamoto, M., Hoshino, T., Kitasato, Y., Sakazaki, Y., Kawayama, T., Fujimoto, K., Ohshima, K., Shiraishi, H., Uchida, M., Ono, J., Ohta, S., Kato, S., Izuhara, K., Aizawa, H., Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur. Respir. J. 37:5 (2011), 1119–1127.
105. Passalacqua, G., Mincarini, M., Colombo, D., Troisi, G., Ferrari, M., Bagnasco, D., Balbi, F., Riccio, A., Canonica, G.W., IL-13 and idiopathic pulmonary fibrosis: possible links and new therapeutic strategies. Pulm. Pharmacol. Ther. 45 (2017), 95–100.
106. Tajiri, M., Okamoto, M., Fujimoto, K., Johkoh, T., Ono, J., Tominaga, M., Azuma, K., Kawayama, T., Ohta, S., Izuhara, K., Hoshino, T., Serum level of periostin can predict long-term outcome of idiopathic pulmonary fibrosis. Res. Invest. 53:2 (2015), 73–81.
107. Naik, P.K., Bozyk, P.D., Bentley, J.K., Popova, A.P., Birch, C.M., Wilke, C.A., Fry, C.D., White, E.S., Sisson, T.H., Tayob, N., Carnemolla, B., Orecchia, P., Flaherty, K.R., Hershenson, M.B., Murray, S., Martinez, F.J., Moore, B.B., Investigators, C., Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am. J. Phys. Lung Cell. Mol. Phys. 303:12 (2012), L1046–56.
108. Ohta, S., Okamoto, M., Fujimoto, K., Sakamoto, N., Takahashi, K., Yamamoto, H., Kushima, H., Ishii, H., Akasaka, K., Ono, J., Kamei, A., Azuma, Y., Matsumoto, H., Yamaguchi, Y., Aihara, M., Johkoh, T., Kawaguchi, A., Ichiki, M., Sagara, H., Kadota, J.I., Hanaoka, M., Hayashi, S.I., Kohno, S., Hoshino, T., Izuhara, K., Consortium for development of diagnostics for pulmonary fibrosis, the usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS One, 12(3), 2017, e0174547.
109. Pardo, A., Gibson, K., Cisneros, J., Richards, T.J., Yang, Y., Becerril, C., Yousem, S., Herrera, I., Ruiz, V., Selman, M., Kaminski, N., Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med., 2(9), 2005, e251.
110. Kadota, J., Mizunoe, S., Mito, K., Mukae, H., Yoshioka, S., Kawakami, K., Koguchi, Y., Fukushima, K., Kon, S., Kohno, S., Saito, A., Uede, T., Nasu, M., High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir. Med. 99:1 (2005), 111–117.
111. White, E.S., Xia, M., Murray, S., Dyal, R., Flaherty, C.M., Flaherty, K.R., Moore, B.B., Cheng, L., Doyle, T.J., Villalba, J., Dellaripa, P.F., Rosas, I.O., Kurtis, J.D., Martinez, F.J., Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 194:10 (2016), 1242–1251.
112. Prasse, A., Probst, C., Bargagli, E., Zissel, G., Toews, G.B., Flaherty, K.R., Olschewski, M., Rottoli, P., Muller-Quernheim, J., Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179:8 (2009), 717–723.
113. Korthagen, N.M., van Moorsel, C.H., Zanen, P., Ruven, H.J., Grutters, J.C., Evaluation of circulating YKL-40 levels in idiopathic interstitial pneumonias. Lung 192:6 (2014), 975–980.
114. Long, X., He, X., Ohshimo, S., Griese, M., Sarria, R., Guzman, J., Costabel, U., Bonella, F., Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis. Eur. Respir. J., 49(2), 2017.
115. Hozumi, H., Fujisawa, T., Enomoto, N., Nakashima, R., Enomoto, Y., Suzuki, Y., Kono, M., Karayama, M., Furuhashi, K., Murakami, A., Inui, N., Nakamura, Y., Mimori, T., Suda, T., Clinical utility of YKL-40 in polymyositis/dermatomyositis-associated interstitial lung disease. J. Rheumatol. 44:9 (2017), 1394–1401.
116. Vaananen, T., Lehtimaki, L., Vuolteenaho, K., Hamalainen, M., Oksa, P., Vierikko, T., Jarvenpaa, R., Uitti, J., Kankaanranta, H., Moilanen, E., Glycoprotein YKL-40 levels in plasma are associated with fibrotic changes on HRCT in asbestos-exposed subjects. Mediat. Inflamm., 2017, 2017, 1797512.
117. Korthagen, N.M., van Moorsel, C.H., Barlo, N.P., Ruven, H.J., Kruit, A., Heron, M., van den Bosch, J.M., Grutters, J.C., Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis. Respir. Med. 105:1 (2011), 106–113.
118. O'Dwyer, D.N., Armstrong, M.E., Kooblall, M., Donnelly, S.C., Targeting defective toll-like receptor-3 function and idiopathic pulmonary fibrosis. Expert Opin. Ther. Targets 19:4 (2015), 507–514.
119. O'Dwyer, D.N., Armstrong, M.E., Trujillo, G., Cooke, G., Keane, M.P., Fallon, P.G., Simpson, A.J., Millar, A.B., McGrath, E.E., Whyte, M.K., Hirani, N., Hogaboam, C.M., Donnelly, S.C., The toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 188:12 (2013), 1442–1450.
120. Oldham, J.M., Ma, S.F., Martinez, F.J., Anstrom, K.J., Raghu, G., Schwartz, D.A., Valenzi, E., Witt, L., Lee, C., Vij, R., Huang, Y., Strek, M.E., Noth, I., Investigators, I.P., TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 192:12 (2015), 1475–1482.
121. Reynolds, P.R., Kasteler, S.D., Cosio, M.G., Sturrock, A., Huecksteadt, T., Hoidal, J.R., RAGE: developmental expression and positive feedback regulation by Egr-1 during cigarette smoke exposure in pulmonary epithelial cells. Am. J. Phys. Lung Cell. Mol. Phys. 294:6 (2008), L1094–101.
122. Yang, Z., Yan, W.X., Cai, H., Tedla, N., Armishaw, C., Di Girolamo, N., Wang, H.W., Hampartzoumian, T., Simpson, J.L., Gibson, P.G., Hunt, J., Hart, P., Hughes, J.M., Perry, M.A., Alewood, P.F., Geczy, C.L., S100A12 provokes mast cell activation: a potential amplification pathway in asthma and innate immunity. J. Allergy Clin. Immunol. 119:1 (2007), 106–114.
123. Wittkowski, H., Sturrock, A., van Zoelen, M.A., Viemann, D., van der Poll, T., Hoidal, J.R., Roth, J., Foell, D., Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome. Crit. Care Med. 35:5 (2007), 1369–1375.
124. Queisser, M.A., Kouri, F.M., Konigshoff, M., Wygrecka, M., Schubert, U., Eickelberg, O., Preissner, K.T., Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am. J. Respir. Cell Mol. Biol. 39:3 (2008), 337–345.
125. Richards, T.J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L.J., Lindell, K.O., Klesen, M., Zhang, Y., Gibson, K.F., Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 185:1 (2012), 67–76.
126. Cole, A.M., Waring, A.J., The role of defensins in lung biology and therapy. Am. J. Respir. Med. 1:4 (2002), 249–259.
127. Konishi, K., Gibson, K.F., Lindell, K.O., Richards, T.J., Zhang, Y., Dhir, R., Bisceglia, M., Gilbert, S., Yousem, S.A., Song, J.W., Kim, D.S., Kaminski, N., Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 180:2 (2009), 167–175.
128. Mukae, H., Iiboshi, H., Nakazato, M., Hiratsuka, T., Tokojima, M., Abe, K., Ashitani, J., Kadota, J., Matsukura, S., Kohno, S., Raised plasma concentrations of alpha-defensins in patients with idiopathic pulmonary fibrosis. Thorax 57:7 (2002), 623–628.
129. Sakamoto, N., Ishimatsu, Y., Kakugawa, T., Yura, H., Tomonaga, M., Harada, T., Nakashima, S., Hara, S., Hara, A., Ishimoto, H., Yatera, K., Mukae, H., Kohno, S., Elevated plasma alpha-defensins in patients with acute exacerbation of fibrotic interstitial pneumonia. Respir. Med. 109:2 (2015), 265–271.
130. Kahloon, R.A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D.J., Bon, J., Soejima, M., Levesque, M.C., Lindell, K.O., Gibson, K.F., Kaminski, N., Banga, G., Oddis, C.V., Pilewski, J.M., Sciurba, F.C., Donahoe, M., Zhang, Y., Duncan, S.R., Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am. J. Respir. Crit. Care Med. 187:7 (2013), 768–775.
131. Tanaka, K., Tanaka, Y., Namba, T., Azuma, A., Mizushima, T., Heat shock protein 70 protects against bleomycin-induced pulmonary fibrosis in mice. Biochem. Pharmacol. 80:6 (2010), 920–931.
132. DePianto, D.J., Chandriani, S., Abbas, A.R., Jia, G., N'Diaye, E.N., Caplazi, P., Kauder, S.E., Biswas, S., Karnik, S.K., Ha, C., Modrusan, Z., Matthay, M.A., Kukreja, J., Collard, H.R., Egen, J.G., Wolters, P.J., Arron, J.R., Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 70:1 (2015), 48–56.
133. Vuga, L.J., Tedrow, J.R., Pandit, K.V., Tan, J., Kass, D.J., Xue, J., Chandra, D., Leader, J.K., Gibson, K.F., Kaminski, N., Sciurba, F.C., Duncan, S.R., C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 189:8 (2014), 966–974.
134. Li, F.J., Surolia, R., Li, H., Wang, Z., Kulkarni, T., Liu, G., de Andrade, J.A., Kass, D.J., Thannickal, V.J., Duncan, S.R., Antony, V.B., Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. J. Immunol. 199:5 (2017), 1596–1605.
135. Feghali-Bostwick, C.A., Tsai, C.G., Valentine, V.G., Kantrow, S., Stoner, M.W., Pilewski, J.M., Gadgil, A., George, M.P., Gibson, K.F., Choi, A.M., Kaminski, N., Zhang, Y., Duncan, S.R., Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis. J. Immunol. 179:4 (2007), 2592–2599.
136. Gilani, S.R., Vuga, L.J., Lindell, K.O., Gibson, K.F., Xue, J., Kaminski, N., Valentine, V.G., Lindsay, E.K., George, M.P., Steele, C., Duncan, S.R., CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PLoS One, 5(1), 2010, e8959.
137. Shimizu, Y., Dobashi, K., Endou, K., Ono, A., Yanagitani, N., Utsugi, M., Sano, T., Ishizuka, T., Shimizu, K., Tanaka, S., Mori, M., Decreased interstitial FOXP3(+) lymphocytes in usual interstitial pneumonia with discrepancy of CXCL12/CXCR4 axis. Int. J. Immunopathol. Pharmacol. 23:2 (2010), 449–461.
138. Herazo-Maya, J.D., Noth, I., Duncan, S.R., Kim, S., Ma, S.F., Tseng, G.C., Feingold, E., Juan-Guardela, B.M., Richards, T.J., Lussier, Y., Huang, Y., Vij, R., Lindell, K.O., Xue, J., Gibson, K.F., Shapiro, S.D., Garcia, J.G., Kaminski, N., Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci. Transl. Med., 5(205), 2013, 205ra136.
139. Milger, K., Yu, Y., Brudy, E., Irmler, M., Skapenko, A., Mayinger, M., Lehmann, M., Beckers, J., Reichenberger, F., Behr, J., Eickelberg, O., Konigshoff, M., Krauss-Etschmann, S., Pulmonary CCR2+CD4+ T cells are immune regulatory and attenuate lung fibrosis development. Thorax 72:11 (2017), 1007–1020.
140. Kotsianidis, I., Nakou, E., Bouchliou, I., Tzouvelekis, A., Spanoudakis, E., Steiropoulos, P., Sotiriou, I., Aidinis, V., Margaritis, D., Tsatalas, C., Bouros, D., Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 179:12 (2009), 1121–1130.
141. Reilkoff, R.A., Peng, H., Murray, L.A., Peng, X., Russell, T., Montgomery, R., Feghali-Bostwick, C., Shaw, A., Homer, R.J., Gulati, M., Mathur, A., Elias, J.A., Herzog, E.L., Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 187:2 (2013), 180–188.
142. Hou, Z., Ye, Q., Qiu, M., Hao, Y., Han, J., Zeng, H., Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis. Respir. Res., 18(1), 2017, 170.
143. Hewitt, R.J., Molyneaux, P.L., The respiratory microbiome in idiopathic pulmonary fibrosis. Ann. Transl. Med., 5(12), 2017, 250.
144. Molyneaux, P.L., Maher, T.M., Respiratory microbiome in IPF: cause, effect, or biomarker?. Lancet Respir. Med. 2:7 (2014), 511–513.
145. Molyneaux, P.L., Cox, M.J., Willis-Owen, S.A., Mallia, P., Russell, K.E., Russell, A.M., Murphy, E., Johnston, S.L., Schwartz, D.A., Wells, A.U., Cookson, W.O., Maher, T.M., Moffatt, M.F., The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 190:8 (2014), 906–913.
146. Han, M.K., Zhou, Y., Murray, S., Tayob, N., Noth, I., Lama, V.N., Moore, B.B., White, E.S., Flaherty, K.R., Huffnagle, G.B., Martinez, F.J., Investigators, C., Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir. Med. 2:7 (2014), 548–556.
147. Faner, R., Sibila, O., Agusti, A., Bernasconi, E., Chalmers, J.D., Huffnagle, G.B., Manichanh, C., Molyneaux, P.L., Paredes, R., Perez Brocal, V., Ponomarenko, J., Sethi, S., Dorca, J., Monso, E., The microbiome in respiratory medicine: current challenges and future perspectives. Eur. Respir. J., 49(4), 2017.
148. Huang, Y., Ma, S.F., Espindola, M.S., Vij, R., Oldham, J.M., Huffnagle, G.B., Erb-Downward, J.R., Flaherty, K.R., Moore, B.B., White, E.S., Zhou, T., Li, J., Lussier, Y.A., Han, M.K., Kaminski, N., Garcia, J.G.N., Hogaboam, C.M., Martinez, F.J., Noth, I., Investigators, C.-I., Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 196:2 (2017), 208–219.
149. Molyneaux, P.L., Cox, M.J., Wells, A.U., Kim, H.C., Ji, W., Cookson, W.O., Moffatt, M.F., Kim, D.S., Maher, T.M., Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir. Res., 18(1), 2017, 29.
150. Kitsios, G.D., Rojas, M., Kass, D.J., Fitch, A., Sembrat, J.C., Qin, S., Veraldi, K.L., Gibson, K.F., Lindell, K., Pilewski, J.M., Methe, B., Li, K., McDyer, J., McVerry, B.J., Morris, A., Microbiome in lung explants of idiopathic pulmonary fibrosis: a case-control study in patients with end-stage fibrosis. Thorax, 2017.
151. Tzouvelekis, A., Kaminski, N., Epigenetics in idiopathic pulmonary fibrosis. Biochem. Cell Biol. 93:2 (2015), 159–170.
152. Xie, T., Liang, J., Geng, Y., Liu, N., Kurkciyan, A., Kulur, V., Leng, D., Deng, N., Liu, Z., Song, J., Chen, P., Noble, P.W., Jiang, D., MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis. Am. J. Respir. Cell Mol. Biol. 57 (2017), 721–732.
153. Cushing, L., Kuang, P., Lu, J., The role of miR-29 in pulmonary fibrosis. Biochem. Cell Biol. 93:2 (2015), 109–118.
154. Pandit, K.V., Corcoran, D., Yousef, H., Yarlagadda, M., Tzouvelekis, A., Gibson, K.F., Konishi, K., Yousem, S.A., Singh, M., Handley, D., Richards, T., Selman, M., Watkins, S.C., Pardo, A., Ben-Yehudah, A., Bouros, D., Eickelberg, O., Ray, P., Benos, P.V., Kaminski, N., Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 182:2 (2010), 220–229.
155. Pandit, K.V., Milosevic, J., Kaminski, N., MicroRNAs in idiopathic pulmonary fibrosis. Transl. Res. 157:4 (2011), 191–199.
156. Li, P., Zhao, G.Q., Chen, T.F., Chang, J.X., Wang, H.Q., Chen, S.S., Zhang, G.J., Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis. J. Asthma 50:9 (2013), 960–964.
157. Milosevic, J., Pandit, K., Magister, M., Rabinovich, E., Ellwanger, D.C., Yu, G., Vuga, L.J., Weksler, B., Benos, P.V., Gibson, K.F., McMillan, M., Kahn, M., Kaminski, N., Profibrotic role of miR-154 in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 47:6 (2012), 879–887.
158. Bratic, A., Larsson, N.G., The role of mitochondria in aging. J. Clin. Invest. 123:3 (2013), 951–957.
159. Kim, S.J., Cheresh, P., Jablonski, R.P., Williams, D.B., Kamp, D.W., The role of mitochondrial DNA in mediating alveolar epithelial cell apoptosis and pulmonary fibrosis. Int. J. Mol. Sci. 16:9 (2015), 21486–21519.
160. Aggarwal, S., Mannam, P., Zhang, J., Differential regulation of autophagy and mitophagy in pulmonary diseases. Am. J. Phys. Lung Cell. Mol. Phys. 311:2 (2016), L433–52.
161. Bueno, M., Lai, Y.C., Romero, Y., Brands, J., St Croix, C.M., Kamga, C., Corey, C., Herazo-Maya, J.D., Sembrat, J., Lee, J.S., Duncan, S.R., Rojas, M., Shiva, S., Chu, C.T., Mora, A.L., PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J. Clin. Invest. 125:2 (2015), 521–538.
162. Maeda, A., Fadeel, B., Mitochondria released by cells undergoing TNF-alpha-induced necroptosis act as danger signals. Cell Death Dis., 5, 2014, e1312.
163. Garcia-Martinez, I., Santoro, N., Chen, Y., Hoque, R., Ouyang, X., Caprio, S., Shlomchik, M.J., Coffman, R.L., Candia, A., Mehal, W.Z., Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9. J. Clin. Invest. 126:3 (2016), 859–864.
164. Gu, X., Wu, G., Yao, Y., Zeng, J., Shi, D., Lv, T., Luo, L., Song, Y., Intratracheal administration of mitochondrial DNA directly provokes lung inflammation through the TLR9-p38 MAPK pathway. Free Radic. Biol. Med. 83 (2015), 149–158.
165. Kirillov, V., Siler, J.T., Ramadass, M., Ge, L., Davis, J., Grant, G., Nathan, S.D., Jarai, G., Trujillo, G., Sustained activation of toll-like receptor 9 induces an invasive phenotype in lung fibroblasts: Possible implications in idiopathic pulmonary fibrosis. Am. J. Pathol. 185:4 (2015), 943–957.
166. Chrysanthopoulou, A., Mitroulis, I., Apostolidou, E., Arelaki, S., Mikroulis, D., Konstantinidis, T., Sivridis, E., Koffa, M., Giatromanolaki, A., Boumpas, D.T., Ritis, K., Kambas, K., Neutrophil extracellular traps promote differentiation and function of fibroblasts. J. Pathol. 233:3 (2014), 294–307.
167. Krychtiuk, K.A., Ruhittel, S., Hohensinner, P.J., Koller, L., Kaun, C., Lenz, M., Bauer, B., Wutzlhofer, L., Draxler, D.F., Maurer, G., Huber, K., Wojta, J., Heinz, G., Niessner, A., Speidl, W.S., Mitochondrial DNA and toll-like Receptor-9 are associated with mortality in critically ill patients. Crit. Care Med. 43:12 (2015), 2633–2641.
168. Ryu, C., Sun, H., Gulati, M., Herazo-Maya, J.D., Chen, Y., Osafo-Addo, A., Brandsdorfer, C., Winkler, J., Blaul, C., Faunce, J., Pan, H., Woolard, T., Tzouvelekis, A., Antin-Ozerkis, D.E., Puchalski, J.T., Slade, M., Gonzalez, A.L., Bogenhagen, D.F., Kirillov, V., Feghali-Bostwick, C., Gibson, K., Lindell, K., Herzog, R.I., Dela Cruz, C.S., Mehal, W., Kaminski, N., Herzog, E.L., Trujillo, G., Extracellular mitochondrial DNA is generated by fibroblasts and predicts death in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 196:12 (2017), 1571–1581.
169. Hisata, S., Kimura, Y., Shibata, N., Ono, S., Kobayashi, T., Chiba, S., Ohta, H., Nukiwa, T., Ebina, M., A normal range of KL-6/MUC1 independent of elevated SP-D indicates a better prognosis in the patients with honeycombing on high-resolution computed tomography. Pulm. Med., 2011, 2011, 806014.
170. Oak, S.R., Murray, L., Herath, A., Sleeman, M., Anderson, I., Joshi, A.D., Coelho, A.L., Flaherty, K.R., Toews, G.B., Knight, D., Martinez, F.J., Hogaboam, C.M., A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One, 6(6), 2011, e21253.
171. De Lauretis, A., Renzoni, E.A., Molecular biomarkers in interstitial lung diseases. Mol. Diagn. Ther. 18:5 (2014), 505–522.
172. Robbie, H., Daccord, C., Chua, F., Devaraj, A., Evaluating disease severity in idiopathic pulmonary fibrosis. Eur. Respir. Rev., 26(145), 2017.
173. Kinder, B.W., Brown, K.K., McCormack, F.X., Ix, J.H., Kervitsky, A., Schwarz, M.I., King, T.E. Jr., Serum surfactant protein-a is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest 135:6 (2009), 1557–1563.
174. Maher, T.M., Oballa, E., Simpson, J.K., Porte, J., Habgood, A., Fahy, W.A., Flynn, A., Molyneaux, P.L., Braybrooke, R., Divyateja, H., Parfrey, H., Rassl, D., Russell, A.M., Saini, G., Renzoni, E.A., Duggan, A.M., Hubbard, R., Wells, A.U., Lukey, P.T., Marshall, R.P., Jenkins, R.G., An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir. Med. 5:12 (2017), 946–955.
175. Herazo-Maya, J.D., Sun, J., Molyneaux, P.L., Li, Q., Villalba, J.A., Tzouvelekis, A., Lynn, H., Juan-Guardela, B.M., Risquez, C., Osorio, J.C., Yan, X., Michel, G., Aurelien, N., Lindell, K.O., Klesen, M.J., Moffatt, M.F., Cookson, W.O., Zhang, Y., Garcia, J.G.N., Noth, I., Prasse, A., Bar-Joseph, Z., Gibson, K.F., Zhao, H., Herzog, E.L., Rosas, I.O., Maher, T.M., Kaminski, N., Validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis: an international, multicentre, cohort study. Lancet Respir. Med. 5:11 (2017), 857–868.
176. Gondhalekar, C., Rajwa, B., Patsekin, V., Ragheb, K., Sturgis, J., Robinson, J.P., Alternatives to current flow cytometry data analysis for clinical and research studies. Methods, S1046-2023(17), 2018, 30168, 10.1016/j.ymeth.2017.12.009 (Epub ahead of print).